Core Viewpoint - The recent market fluctuations are influenced by the Federal Reserve's hawkish stance and concerns over AI market trends, leading to a correction in technology stocks and a rotation of funds towards sectors like lithium batteries and consumer goods [1] Group 1: Market Overview - The overseas market is experiencing overall volatility, with technology stocks undergoing a correction phase [1] - The end of the longest U.S. government shutdown has raised attention on upcoming key economic data and its potential impact on overseas markets [1] - A-share market continues in a consolidation pattern, with rapid sector rotation and a focus on themes like lithium batteries and consumer sectors benefiting from policy support [1] Group 2: Investment Strategy - It is recommended to focus on themes such as anti-involution and dividends during sector rotations, with an emphasis on technology sectors that are poised for a rebound [2] - The anti-involution area is becoming a key focus for macroeconomic regulation, enhancing the long-term investment value of related sectors [2] - The consumption sector is crucial for stabilizing the economic foundation, with particular attention on service consumption and new consumption models [2] Group 3: Economic Indicators - The recent surge in the lithium battery supply chain reflects a tightening supply-demand balance, boosting mid-term economic improvement expectations [1] - Financial data from October confirms signals of fund migration, suggesting a favorable liquidity outlook [1] - The anticipated policy implementations and rising price expectations are expected to clarify the logic behind anti-involution sectors, while the technology sector's trends and performance are entering a verification phase [1]

中国银河证券认为，展望未来，市场风险偏好趋于谨慎，场内热点轮动加快，港股或延续震荡走势。配 置方面，建议关注以下板块：1、"反内卷"政策效果逐渐显现，供需格局变化下，商品价格上涨的周期 股或持续反弹。2、美联储降息政策面临较大不确定性，市场风险偏好下降，投资者或转向红利股寻求 防御。 ...

Core Viewpoint - The A-share market is currently in a consolidation phase, with rapid rotation among sectors, particularly as funds shift towards lithium batteries and electrolyte themes, while the consumer sector benefits from favorable policies [1] Sector Analysis - The technology sector, which previously saw significant gains, is now in a state of consolidation, indicating a potential pause in upward momentum [1] - Funds are beginning to rotate towards themes such as lithium batteries and electrolytes, suggesting a shift in investor focus [1] - The consumer sector is experiencing benefits from policy support, although the sustainability of these themes remains in question [1] Market Outlook - As the year-end approaches, institutional allocations are likely to become more balanced, preparing for the economic outlook for the next year [1] - The year-end market is expected to maintain a volatile structure, characterized by fluctuations rather than a clear trend [1] - In the context of sector rotation, opportunities related to "anti-involution" and dividends are highlighted, with a focus on the technology sector's potential for catch-up gains and industry trend catalysts [1]

Focus Review - The People's Bank of China (PBOC) will conduct a 6-month reverse repurchase operation of 800 billion yuan to maintain liquidity in the banking system, resulting in a net injection of 500 billion yuan after accounting for maturing operations [3] - The PBOC has established a pattern of monthly liquidity injections, indicating a continued focus on maintaining a loose monetary environment amid increased growth demands [3] Equity Market - CITIC Securities suggests that China's capital market is transitioning from an emerging market to a mature market, with an increasing global business exposure for listed companies, which is foundational for a low-volatility bull market [5] - Huatai Securities predicts that the A-share profit cycle will likely recover in the first half of 2026, driven by positive signals from capacity inventory cycles and overseas expansion [6] - Galaxy Securities warns of a potential decline in market risk appetite as the year-end approaches, suggesting a focus on cyclical sectors and dividend stocks that may benefit from improved Sino-U.S. trade relations [7] Industry Research - HSBC Jintrust Fund highlights the storage industry as a sector with multiple opportunities, driven by policy shifts and increased demand, particularly from AI data centers, suggesting a strategic opportunity for high growth [12] -招商证券 identifies investment potential in sectors experiencing supply clearing, particularly in resources, consumer goods, and traditional machinery, recommending focus on quality leaders and low-inventory industries [13] - 嘉实基金 sees significant long-term growth potential in China's innovative pharmaceutical sector, suggesting that recent corrections are a market adjustment rather than an end to the growth trend [14] Asset Allocation - Guosen Securities indicates that the bull market may be entering its second phase, with economic conditions improving and a broadening market trend, particularly in technology and undervalued sectors like liquor and real estate [22]

Market Performance - The Hong Kong stock market showed mixed performance from November 10 to November 14, with the Hang Seng Index rising by 1.26% to 26,572.46 points, while the Hang Seng Tech Index fell by 0.42%, and the Hang Seng China Enterprises Index increased by 1.41% [1][2] - Among the primary sectors, seven sectors saw gains while four experienced declines, with real estate, healthcare, and consumer goods leading the gains at 5.58%, 5.13%, and 4.74% respectively [2] Liquidity Analysis - The average daily trading volume on the Hong Kong Stock Exchange was HKD 233.12 billion, an increase of HKD 2.59 billion from the previous week, while the average short-selling amount decreased by HKD 1.11 billion to HKD 28.36 billion [3] - The net inflow of southbound funds totaled HKD 24.77 billion, a decrease of HKD 13.91 billion compared to the previous week [3] Valuation and Risk Appetite - As of November 14, the Hang Seng Index had a PE ratio of 12.05 and a PB ratio of 1.24, reflecting increases of 1.53% and 1.44% respectively, placing it at the 86% and 91% percentile levels since 2019 [4] - The risk premium for the Hang Seng Index was recorded at 4.16%, which is significantly below the three-year rolling average [4] Investment Outlook - The market is expected to maintain a cautious risk appetite, with a rotation of hot sectors anticipated, leading to a potential continuation of a volatile trading environment [5] - Investment recommendations include focusing on cyclical stocks that may rebound due to changing supply-demand dynamics and dividend stocks as a defensive strategy amid uncertainties regarding U.S. Federal Reserve interest rate policies [5]

Market Performance - The Hang Seng Index increased by 1.26% this week, closing at 26,572.46 points, while the Tech Index decreased by 0.42% to 5,812.80 points, and the National Enterprises Index rose by 1.41% to 9,397.96 points [2][4]. Market Dynamics - The fluctuations in the Hong Kong stock market are closely related to external environments, particularly the impact of the U.S. government shutdown, which temporarily locked nearly one trillion dollars in liquidity, raising the cost of dollar funds and pressuring risk assets like U.S. and Hong Kong stocks [4]. - A recent report from Western Securities suggests that the end of the U.S. government shutdown may release previously "frozen" dollar liquidity, potentially leading to a liquidity-driven rally in the Hong Kong stock market [4]. Capital Inflows - Southbound capital has provided strong support, with net purchases through the Stock Connect exceeding HKD 1.3 trillion this year, totaling over HKD 5 trillion, indicating a shift towards a "semi-onshore market" where domestic capital plays a more significant role in pricing [4]. Sector Performance - Pharmaceutical stocks have seen renewed interest, with notable gains: - Gilead Sciences (01672.HK) up 45.40% - Clover Biopharmaceuticals (02197.HK) up 29.95% - Yummy (02589.HK) up 18.81% - The positive performance is attributed to strong Q3 results in innovative drugs and life sciences sectors [5]. - Other notable performers include: - HuShang Ayi (02589.HK) up 31.44% due to a new ten-year H-share incentive plan and reaching over 10,739 stores [5]. - Lee & Man Paper (00746.HK) up 17.37% benefiting from rising paper prices [5]. - Conversely, companies like Sanhua Intelligent Control (02050.HK) and Legend Holdings (06683.HK) faced declines of 10.93% and 19.82%, respectively, due to market risk aversion and concerns over equity dilution from a recent share placement [5]. Gold and Automotive Sectors - Gold stocks weakened following hawkish comments from Federal Reserve officials, with China Gold International (02099.HK) down 3.94% and Zijin Mining (02899.HK) down 2.94% [6][7]. - The automotive sector also faced declines, with Xpeng Motors (09868.HK) down 6.80% amid a drop in retail sales of passenger cars by 19% year-on-year for the first nine days of November [10][11]. Brokerage and Semiconductor Stocks - Chinese brokerage stocks adjusted, with major firms like GF Securities (01776.HK) and China Galaxy (06881.HK) experiencing declines due to a significant drop in new account openings [13]. - Semiconductor stocks also fell, influenced by a broader sell-off in U.S. tech stocks, with Shanghai Fudan (01385.HK) down 5.92% and SMIC (00981.HK) down 2.78% [14][16]. Individual Stock Movements - Lehua Entertainment (02306.HK) rose nearly 8% amid speculation regarding a contract renewal with a prominent artist [18]. - Zhonghui Biopharmaceuticals (02627.HK) increased by over 6% after announcing the initiation of Phase I clinical trials for its flu vaccines [19].

Core Insights - The Southeast Asian snack market has surpassed 150 billion RMB, with a compound annual growth rate (CAGR) exceeding GDP growth over the past decade, presenting significant investment opportunities [1][2] - The market can be categorized into three segments: growth markets (Indonesia, Philippines, Vietnam), late growth markets (Thailand, Malaysia, Singapore), and nurturing markets (Laos, Myanmar, Cambodia) [1][2] Market Overview - Indonesia's snack market is valued at 50 billion RMB, with sweet snacks dominating but experiencing slowing growth, while flavored snacks are rapidly increasing [2] - The Philippines has a market size of 30 billion RMB, with a high concentration of local brands in the flavored snack segment [2] - Vietnam's market is worth 15 billion RMB, with a balanced share between sweet and flavored snacks, featuring a more fragmented market with a dominance of foreign brands [2] - Thailand's snack market is valued at 24 billion RMB, primarily driven by flavored snacks, with a fragmented market structure [2] - Malaysia's market is around 10 billion RMB, with a high proportion of sweet snacks and a relatively concentrated market [2] Company Strategies - Companies venturing into Southeast Asia can focus on markets with "market expansion," "undetermined structure," and "category adaptation," with Indonesia, Vietnam, and Thailand as primary targets for growth [2][3] - Successful companies like Calbee and Glico have adopted localized strategies, with Calbee focusing on local brand adaptations and partnerships in Indonesia and Thailand, while Glico emphasizes a unified market approach with localized product modifications [3][4] Domestic Implications - Notable Chinese snack companies such as Qiaqia Food, Ganyuan Food, and others are actively expanding into Southeast Asia, primarily targeting Thailand, Indonesia, and Vietnam [4] - These companies are leveraging their product strengths, localizing flavors and branding, and utilizing a combination of distribution channels including e-commerce and local partnerships [4]

Group 1 - The core viewpoint of the article highlights that social financing (社融) has shown a year-on-year decrease, with a stable but slowing growth rate [1] - The main drag on the increase in social financing is attributed to the decline in RMB loans and government bond issuance [1] - There is a continued weak demand for financing in the real sector, with a notable increase in bill financing [1] - The growth rates of M1 and M2 have slowed down, indicating a trend of deposit migration [1]

Core Viewpoint - China Galaxy Securities reports that Innovent Biologics (01801) has become a leading biopharma company in China, excelling in innovative drug R&D, production, and commercialization, particularly in the oncology sector, which is expected to drive growth [1] Group 1: Financial Projections - The company is projected to achieve revenues of 11.891 billion, 14.836 billion, and 20.029 billion yuan for the years 2025, 2026, and 2027 respectively, with net profits of 0.824 billion, 1.378 billion, and 2.059 billion yuan for the same years [1] Group 2: Strategic Partnership with Takeda - On October 22, 2025, Innovent Biologics entered a global strategic partnership with Takeda Pharmaceutical to accelerate the global rollout of next-generation IO and ADC therapies, including IBI363, IBI343, and IBI3001, with an upfront payment of 1.2 billion USD and potential milestone payments totaling up to 11.4 billion USD [1] Group 3: Development of IBI363 - Innovent will co-develop IBI363 with Takeda, sharing development costs at a 40/60 ratio, and profits in the U.S. market will also be split 40/60, with Takeda leading the development [2] - IBI363 has shown promising data at the 2025 ASCO meeting, with a cORR of 36.7%, mPFS of 9.3 months, and a 12-month OS rate of 70.9%, with a global Phase III clinical plan set to launch soon [2] Group 4: Rights Granted for IBI343 and IBI3001 - Innovent has granted Takeda exclusive rights to IBI343 outside of Greater China, with potential milestone payments and high-tier sales sharing [3] - Takeda will focus on the global development of IBI343, particularly in first-line gastric and pancreatic cancer, while IBI3001's rights outside Greater China are also available for Takeda to exercise in the future [3]

Core Viewpoint - Xinda Biopharma has established itself as a leading player in China's biopharmaceutical sector, particularly in the oncology field, and is expected to continue its growth trajectory with new strategic partnerships and product developments [1] Group 1: Strategic Partnership - On October 22, 2025, Xinda Biopharma entered into a global strategic collaboration with Takeda Pharmaceutical to accelerate the global rollout of next-generation IO and ADC therapies, involving three products: IBI363, IBI343, and IBI3001 [1] - The collaboration includes an upfront payment of $1.2 billion (including a $100 million premium for strategic equity investment) and potential milestone payments, with a total deal value reaching up to $11.4 billion [1] Group 2: Product Development and Commercialization - Xinda will co-develop IBI363 with Takeda, sharing development costs at a 40/60 ratio and splitting profits from commercialization in the U.S. market similarly [2] - IBI363 has shown promising data at the 2025 ASCO conference, with a cORR of 36.7%, mPFS of 9.3 months, and a 12-month OS rate of 70.9% for immune-resistant NSCLC, with a global Phase III clinical plan set to launch soon [2] Group 3: ADC Product Rights - Xinda granted Takeda exclusive rights to IBI343 outside of Greater China, which includes potential milestone payments and high-tier percentage sales sharing [3] - IBI343 is currently undergoing Phase III clinical trials for gastric cancer in China and Japan, and has completed global Phase I/II trials for PDAC [3] - Additionally, Xinda has granted Takeda an option for early pipeline IBI3001 outside of Greater China, which could yield option fees, milestone payments, and high-tier sales sharing if exercised [3]